According to a new study published by the Journal of Steroid Biochemistry and Molecular Biology, patients with the CCP (Chinese Communist Party) Virus (COVID-19) who have an acute respiratory infections, may improve if given vitamin D3, hydroxychloroquine, and azithromycin.
The research used a randomized controlled trial in patients suffering from CCP Virus-related pneumonia at a hospital in Spain.
All patients selected for the research were given hydroxychloroquine and azithromycin, and a group of them were also given vitamin D3 (calcifediol).
According to the Washington Examiner, hydroxychloroquine is an “ionophore” that can transport certain molecules across a cell membrane, while azithromycin is an antibiotic used to treat lung infections.
Among the 50 patients who were treated with vitamin D3, only two were admitted to an intensive care unit, while among the 26 patients who did not receive vitamin D3, 13 were hospitalized and two of them died.
The study was limited to the sample of 76 patients, so it is unclear how effective vitamin D3 with hydroxychloroquine is in treating patients with an acute respiratory infection.
Hydroxychloroquine has played an important role in treating the infections of patients with the CCP Virus. According to a study released on Friday, Sept. 4, by the Centers for Disease Control and Prevention (CDC), prescriptions that include hydroxychloroquine as a treatment have increased 80-fold since March.
“New prescriptions from specialists who didn’t normally prescribe the drugs rose from 1,143 in February to 75,569 in March, an eightyfold year-over-year increase,” detailed Forbes magazine.
According to ABC News, President Donald Trump, known for promoting the use of the drug, authorized the Food and Drug Administration (FDA) for its use early in the pandemic
“HYDROXYCHLOROQUINE & AZITHROMYCIN, taken together, have a real chance to be one of the biggest game changers in the history of medicine. The FDA has moved mountains—Thank You! Hopefully they will BOTH … be put in use IMMEDIATELY. PEOPLE ARE DYING, MOVE FAST, and GOD BLESS EVERYONE!,” President Trump tweeted in early March.
Harvey A. Risch, M.D., Ph.D., professor of epidemiology at the Yale School of Public Health, has said based on recent findings hydroxychloroquine “has been widely misrepresented in both clinical reports and public media.”
In an article by the Yale School of Public Health, indicates, “Five studies, including two controlled clinical trials, have demonstrated significant major outpatient treatment efficacy. Hydroxychloroquine+azithromycin has been used as standard-of-care in more than 300,000 older adults with multicomorbidities.”